UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The roles of FLT3 in hematopoiesis and leukemia

Blood, 2002-09, Vol.100 (5), p.1532-1542

2002

Volltextzugriff (PDF)

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

Blood, 2011-03, Vol.117 (12), p.3421-3429

2011

Volltextzugriff (PDF)

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

The New England journal of medicine, 2006-06, Vol.354 (24), p.2542-2551

2006

Volltextzugriff (PDF)

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

Blood, 2005-07, Vol.106 (2), p.721-724

2005

Volltextzugriff (PDF)

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Blood, 2007-06, Vol.109 (11), p.5011-5015

2007

Volltextzugriff (PDF)

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

Clinical cancer research, 2005-07, Vol.11 (13), p.4941-4947

2005

Volltextzugriff (PDF)

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species

Blood, 2005-02, Vol.105 (4), p.1717-1723

2005

Volltextzugriff (PDF)

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells

Blood, 2008-04, Vol.111 (7), p.3723-3734

2008

Volltextzugriff (PDF)

ARG tyrosine kinase activity is inhibited by STI571

Blood, 2001-04, Vol.97 (8), p.2440-2448

2001

Volltextzugriff (PDF)

Molecular mechanisms of transformation by the BCR-ABL oncogene

Seminars in hematology, 2003-04, Vol.40 (2), p.4-10

2003

Volltextzugriff (PDF)

The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development

Blood, 2007-11, Vol.110 (10), p.3618-3623

2007

Volltextzugriff (PDF)

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a

Blood, 2004-06, Vol.103 (12), p.4622-4629

2004

Volltextzugriff (PDF)

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

Blood, 2004-04, Vol.103 (7), p.2802-2805

2004

Volltextzugriff (PDF)

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies

Blood, 2005-01, Vol.105 (1), p.22-30

2005

Volltextzugriff (PDF)

A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets

Clinical cancer research, 2014-03, Vol.20 (5), p.1135-1145

2014

Volltextzugriff (PDF)

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

Blood, 2005-01, Vol.105 (1), p.54-60

2005

Volltextzugriff (PDF)

c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions

Cancer research (Chicago, Ill.), 2003-10, Vol.63 (19), p.6272-6281

2003

Volltextzugriff (PDF)

Mechanisms of transformation by the BCR/ABL oncogene

International journal of hematology, 2001-04, Vol.73 (3), p.278-291

2001

Volltextzugriff (PDF)

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin

Blood, 2002-11, Vol.100 (10), p.3767-3775

2002

Volltextzugriff (PDF)

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

Cancer research (Chicago, Ill.), 2005-10, Vol.65 (19), p.8968-8974

2005

Volltextzugriff (PDF)

Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia

Cancer research (Chicago, Ill.), 2004-09, Vol.64 (18), p.6385-6389

2004

Volltextzugriff (PDF)

Role of FLT3 in leukemia

Current opinion in hematology, 2002-07, Vol.9 (4), p.274-281

2002

Volltextzugriff (PDF)

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

Blood, 2007-03, Vol.109 (5), p.2112-2120

2007

Volltextzugriff (PDF)

1 – 25 von 269

Suche als RSS-Feed

Aktive Filter

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(257)
Mit Volltextzugriff
(224)

Publikationsform

Sprache

Englisch
(269)
Japanisch
(60)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(267)
Science & Technology
(230)
Life Sciences & Biomedicine
(227)
Humans
(221)
Female
(138)
Male
(133)
Middle Aged
(99)
Adult
(96)
Hematologic And Hematopoietic Diseases
(70)
Aged
(67)
Pharmacology. Drug Treatments
(63)
Hematology
(61)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(55)
Animals
(45)
Cardiovascular System & Cardiology
(40)
Cardiac & Cardiovascular Systems
(38)
Adolescent
(32)
Antineoplastic Agents
(32)
Mice
(32)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The roles of FLT3 in hematopoiesis and leukemia

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells

ARG tyrosine kinase activity is inhibited by STI571

Molecular mechanisms of transformation by the BCR-ABL oncogene

The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies

A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions

Mechanisms of transformation by the BCR/ABL oncogene

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia

Role of FLT3 in leukemia

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

Aktive Filter

Suchergebnisse filtern